These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33914735)

  • 1. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
    Zhu X; Mannar D; Srivastava SS; Berezuk AM; Demers JP; Saville JW; Leopold K; Li W; Dimitrov DS; Tuttle KS; Zhou S; Chittori S; Subramaniam S
    PLoS Biol; 2021 Apr; 19(4):e3001237. PubMed ID: 33914735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.
    Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Tuttle KS; Marquez AC; Sekirov I; Subramaniam S
    Science; 2022 Feb; 375(6582):760-764. PubMed ID: 35050643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function.
    Yang TJ; Yu PY; Chang YC; Liang KH; Tso HC; Ho MR; Chen WY; Lin HT; Wu HC; Hsu SD
    Nat Struct Mol Biol; 2021 Sep; 28(9):731-739. PubMed ID: 34385690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants.
    Saville JW; Mannar D; Zhu X; Srivastava SS; Berezuk AM; Demers JP; Zhou S; Tuttle KS; Sekirov I; Kim A; Li W; Dimitrov DS; Subramaniam S
    Nat Commun; 2022 Feb; 13(1):742. PubMed ID: 35136050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.
    Xue S; Han Y; Wu F; Wang Q
    Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 10. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
    Barnes CO; Jette CA; Abernathy ME; Dam KA; Esswein SR; Gristick HB; Malyutin AG; Sharaf NG; Huey-Tubman KE; Lee YE; Robbiani DF; Nussenzweig MC; West AP; Bjorkman PJ
    Nature; 2020 Dec; 588(7839):682-687. PubMed ID: 33045718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
    Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.
    Yajima H; Anraku Y; Kaku Y; Kimura KT; Plianchaisuk A; Okumura K; Nakada-Nakura Y; Atarashi Y; Hemmi T; Kuroda D; Takahashi Y; Kita S; Sasaki J; Sumita H; ; Ito J; Maenaka K; Sato K; Hashiguchi T
    Nat Commun; 2024 Oct; 15(1):8574. PubMed ID: 39375326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
    Niu S; Zhao Z; Liu Z; Rong X; Chai Y; Bai B; Han P; Shang G; Ren J; Wang Y; Zhao X; Liu K; Tian W-x; Wang Q; Gao GF
    J Virol; 2024 Mar; 98(3):e0115723. PubMed ID: 38305152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.
    Cai Y; Zhang J; Xiao T; Lavine CL; Rawson S; Peng H; Zhu H; Anand K; Tong P; Gautam A; Lu S; Sterling SM; Walsh RM; Rits-Volloch S; Lu J; Wesemann DR; Yang W; Seaman MS; Chen B
    Science; 2021 Aug; 373(6555):642-648. PubMed ID: 34168070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.
    Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Kim A; Li W; Dimitrov DS; Subramaniam S
    Cell Rep; 2021 Dec; 37(12):110156. PubMed ID: 34914928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.
    Gobeil SM; Janowska K; McDowell S; Mansouri K; Parks R; Stalls V; Kopp MF; Manne K; Li D; Wiehe K; Saunders KO; Edwards RJ; Korber B; Haynes BF; Henderson R; Acharya P
    Science; 2021 Aug; 373(6555):. PubMed ID: 34168071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
    Gan HH; Twaddle A; Marchand B; Gunsalus KC
    J Mol Biol; 2021 Jul; 433(15):167051. PubMed ID: 33992693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.
    Yang H; Guo H; Wang A; Cao L; Fan Q; Jiang J; Wang M; Lin L; Ge X; Wang H; Zhang R; Liao M; Yan R; Ju B; Zhang Z
    Nat Commun; 2024 Sep; 15(1):7715. PubMed ID: 39231977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.
    Wang Y; Liu C; Zhang C; Wang Y; Hong Q; Xu S; Li Z; Yang Y; Huang Z; Cong Y
    Nat Commun; 2022 Feb; 13(1):871. PubMed ID: 35169135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.